Lupus & antiphospholipid syndrome
Hydroxychloroquine in Lupus Pregnancy and Risk of Preeclampsia
Authors' conclusion
Using a large insurance-based database, we did not observe a decreased risk of preeclampsia associated with HCQ treatment in pregnancy, although we cannot rule out residual and unmeasured confounding and misclassification.
Study context
- Population
- Privately insured patients with systemic lupus erythematosus (SLE) with live birth singleton pregnancies (2007–2016)pregnancies in 1,020 patients
- Participants
- 1,068 live birth singleton pregnancies
- Exposure
- Hydroxychloroquine (HCQ) from 3 months preconception through first trimester vs no HCQ
- Outcome
- Preeclampsia
Methodological detailsinsurance-based database, modified Poisson regression, propensity score-adjusted, stratified by parity
- Insurance-based database
- Modified Poisson regression
- Propensity score-adjusted
- Stratified by parity
Main finding
As reported in the abstract
Preeclampsia, stratified by parity
HCQ vs No HCQRelative risk (95% CI)
Nulliparous pregnancies
1.26(0.82–1.93)
Multiparous pregnancies
1.20(0.80–1.70)
Observational data: associations, not effects.
Original publication
Hydroxychloroquine in Lupus Pregnancy and Risk of Preeclampsia. Arthritis Rheumatol. Published 19 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →